PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

New ‘score’ developed to measure multimorbidity

The National Institute for Health Research (NIHR) has revealed a new “score” for measuring multiple long-term health conditions in patients in primary care.

Researchers from the organisation’s School for Primary Care Research have developed the Cambridge Multimorbidity Score; a transparent, simple measure of multimorbidity that can predict different outcomes in people with multiple conditions.

The institute says that the score could help people planning clinical services or allocating healthcare resources to respond to the needs of patients with multiple health conditions, as around quarter of patients in primary care have multiple conditions.

In 2018, GP leaders called for longer consultation times on the back of an analysis that showed patients with multimorbidities account for more than half of appointments.

The study, which was published in the British Journal of General Practice, looked at data from more than 400,000 GP-registered patients, of which 27.2% were found to have at least two long-term conditions, such as hypertension (18.2%) and chronic pain (10.1%).

According to the data, patients with multimorbidity accounted for 52.9% of GP consultations, 78.7% of prescriptions, and 56.1% of hospital admissions.

The study authors concluded that multimorbidity is “common, socially patterned, and associated with increased health service utilisation,” and that their findings “support the need to improve the quality and efficiency of health services providing care to patients with multimorbidity at both practice and national level.”

Further to the findings, the NIHR reminds that the number of patients with multiple long-term conditions is going up as the population ages, putting pressure on primary and secondary care.

When developing the new score index, researchers modelled how conditions such as hypertension, anxiety or depression affected three key patient outcomes: general practitioner visits, unplanned hospital admissions and death.

As a result, the new score outperforms the most commonly used current measure, the Charlson index, in predicting these three outcomes.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026